SCHEMBL2268036

SCHEMBL2268036

Cc1nn2c(-c3ccccc3)c(C)sc2c1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.40
NPC1 O15118 9/20 0.40
RAB9A P51151 9/20 0.40
KDM4E B2RXH2 8/20 0.40
ALDH1A1 P00352 6/20 0.40
MAPT P10636 5/20 0.40
HPGD P15428 5/20 0.40
TP53 P04637 2/20 0.40
HTT P42858 2/20 0.40
HCRTR1 O43613 1/20 0.40
LMNA P02545 1/20 0.40
CASP1 P29466 2/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CDK8 P49336 1/20 0.38
ACVR1 Q04771 1/20 0.38
NFKB1 P19838 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11656557 0.69 MAPT (0.58) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL13858651 0.66 KDM4E (0.50) SMN1; SMN2NPC1RAB9AKDM4EMAPT
SCHEMBL18752187 0.64 AKT2 (0.44) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL5739917 0.64 KDM4E (0.69) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL7467461 0.62 NPC1 (0.80) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL4614475 0.62 ALDH1A1 (0.52) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL4617250 0.60 ALDH1A1 (0.54) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL4617247 0.60 ALDH1A1 (0.54) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL34059 0.60 SMN1; SMN2 (0.72) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL8041064 0.60 GSK3B (0.46) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1413286-B1 Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent OREAL (FR) 2009-04-22 EP claimed
EP-1413286-A1 Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent L'OREAL (FR) 2004-04-28 EP claimed
EP-2182914-B1 COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF L'ORÉAL (FR) 2017-11-08 EP disclosed
EP-2175830-B1 COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES ORÉAL L (FR) 2015-09-30 EP disclosed
US-8530504-B2 Pyrazolothiazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-09-10 US disclosed
US-8530504-B2 Pyrazolothiazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-09-10 US disclosed
US-8431603-B2 3-phenylpyrazolo[5,1-b]thiazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-04-30 US disclosed
US-8431603-B2 3-phenylpyrazolo[5,1-b]thiazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-04-30 US disclosed
EP-2487178-A1 PYRAZOLOTHIAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2012-08-15 EP disclosed
US-8043385-B2 Composition oxidation colouring of keratinic fibres, containing a cationic cellulose ether, a metasilicate and oxidation dyes, method for oxidation colouring and uses thereof L'OREAL S.A. (FR) 2011-10-25 US disclosed
US-8002847-B2 Composition for oxidation dyeing keratin fibres comprising a cationic cellulose ether, a weakly oxyethylenated sorbitan fatty acid ester and oxidation dyes L 'OREAL S.A. (FR) 2011-08-23 US disclosed
WO-2009128383-A1 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) 2009-10-22 WO disclosed
US-20090259049-A1 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-10-15 US disclosed
US-20090259049-A1 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-10-15 US disclosed
EP-1413286-B1 Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent OREAL (FR) 2009-04-22 EP disclosed
WO-2009019383-A2 COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF L'OREAL (FR) 2009-02-12 WO disclosed
WO-2009016061-A2 COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES L'OREAL (FR) 2009-02-05 WO disclosed
EP-1459732-A1 Dye composition comprising at least one heterocyclic oxidation base and at least one 2,3,5-triaminopyridine as coupler L'OREAL (FR) 2004-09-22 EP disclosed
EP-1413286-A1 Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent L'OREAL (FR) 2004-04-28 EP disclosed
EP-0433854-A2 3-Aminopyrazolo heterocycles, their use for the determination of hydrogen peroxide, hydrogen peroxide forming systems, peroxidase, peroxidant active substances or electron rich aromatic compounds, corresponding determination process and agents Roche Diagnostics GmbH (DE) 1991-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259049-A1 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS CRHR1, AGTR1, CRHR2 SMN1; SMN2 2080/4885NPC1 616/4885RAB9A 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.